A review on orexin receptor antagonists in chronic insomnia: a revolutionary approach
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20260447Keywords:
Chronic insomnia, Orexin receptor antagonists, DORAs, SORAs, Suvorexant, Lemborexant, Daridorexant, Sleep–wake regulation, Hyperarousal, PharmacotherapyAbstract
Chronic insomnia is a chronic sleep disorder characterized by the inability to fall asleep or stay asleep. Other than hyperarousal, altered circadian rhythms, and behavioral changes, it can also occur due to medical or psychiatric conditions. The use of benzodiazepines, Z-drugs, melatonin agonists, antihistamines, and sedative antidepressants as traditional treatment in chronic insomnia offer relief, but are also coupled with several limitations like tolerance, dependence, residual sedation, and disruption of normal sleep architecture. With the continuous revealing of the sleep neurobiology mystery, the orexin system has been pinpointed as a main regulator of wakefulness and arousal, thus making it a probable therapeutic target. Orexin receptor antagonists like suvorexant, lemborexant, and daridorexant inhibit the selective OX1R and OX2R pathways thereby decreasing the wakefulness and facilitating natural, continuous sleep. These medications have shown to enhance sleep by reducing the time to fall asleep, the number of times one wakes up and thereby increasing the total time spent during sleep, without impairing the normal sleep architecture. They are regarded as a breakthrough and more natural means of treating chronic insomnia because of their good safety profile and the low risk of next-day sedation they come with.
Metrics
References
Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3:S7-10. DOI: https://doi.org/10.5664/jcsm.26929
Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep. 1999;22:S347-53.
Mao T, Guo B, Rao H. Unraveling the complex interplay between insomnia, anxiety, and brain networks. Sleep. 2024;47(3):zsad330. DOI: https://doi.org/10.1093/sleep/zsad330
Sateia MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation of chronic insomnia: an American Academy of Sleep Medicine review. Sleep. 2000;23:243-308. DOI: https://doi.org/10.1093/sleep/23.2.1l
Lie JD, Tu KN, Shen DD, Wong BM. Pharmacological treatment of insomnia. P T. 2015;40(11):759-71.
Hassinger AB, Bletnisky N, Dudekula R, El-Solh AA. Selecting a pharmacotherapy regimen for patients with chronic insomnia. Expert Opin Pharmacother. 2020;21(9):1035-43. DOI: https://doi.org/10.1080/14656566.2020.1743265
Inutsuka A, Yamanaka A. The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Front Endocrinol (Lausanne). 2013;4:18. DOI: https://doi.org/10.3389/fendo.2013.00018
Katzman MA, Katzman MP. Neurobiology of the orexin system and its potential role in the regulation of hedonic tone. Brain Sci. 2022;12(2):150. DOI: https://doi.org/10.3390/brainsci12020150
Álamo C, Sáiz Ruiz J, Zaragozá Arnáez C. Orexinergic receptor antagonists as a new therapeutic target to overcome limitations of current pharmacological treatment of insomnia disorder. Actas Esp Psiquiatr. 2024;52(2):172-82. DOI: https://doi.org/10.62641/aep.v52i2.1659
Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26:675-700. DOI: https://doi.org/10.1111/jsr.12594
Naha S, Sivaraman M, Sahota P. Insomnia: a current review. Mo Med. 2024;121(1):44-51.
Levenson JC, Kay DB, Buysse DJ. The pathophysiology of insomnia. Chest. 2015;147(4):1179-92. DOI: https://doi.org/10.1378/chest.14-1617
Khurshid KA. Comorbid insomnia and psychiatric disorders: an update. Innov Clin Neurosci. 2018;15(3-4):28-32.
Memar P, Faradji F. A novel multi-class EEG-based sleep stage classification system. IEEE Trans Neural Syst Rehabil Eng. 2018;26(1):84-95. DOI: https://doi.org/10.1109/TNSRE.2017.2776149
Murillo-Rodríguez E, Arias-Carrión O, Sanguino-Rodríguez K, González-Arias M, Haro R. Mechanisms of sleep-wake cycle modulation. CNS Neurol Disord Drug Targets. 2009;8(4):245-53. DOI: https://doi.org/10.2174/187152709788921654
Watson CJ, Baghdoyan HA, Lydic R. Neuropharmacology of sleep and wakefulness. Sleep Med Clin. 2010;5(4):513-28. DOI: https://doi.org/10.1016/j.jsmc.2010.08.003
Chaput JP, Dutil C, Featherstone R, Ross R, Giangregorio L, Saunders TJ, et al. Sleep timing, sleep consistency, and health in adults: a systematic review. Appl Physiol Nutr Metab. 2020;45(10 Suppl 2):S232-47. DOI: https://doi.org/10.1139/apnm-2020-0032
Schwartz MD, Kilduff TS. The neurobiology of sleep and wakefulness. Psychiatr Clin North Am. 2015;38(4):615-44. DOI: https://doi.org/10.1016/j.psc.2015.07.002
Chang Y, Liu L, Xu X, Zhang S. The pathogenesis and treatment of insomnia combined with depression. Int J Gen Med. 2025;18:4635-45. DOI: https://doi.org/10.2147/IJGM.S547865
Jászberényi M, Thurzó B, Bagosi Z, Vécsei L, Tanaka M. The orexin/hypocretin system, the peptidergic regulator of vigilance, orchestrates adaptation to stress. Biomedicines. 2024;12(2):448. DOI: https://doi.org/10.3390/biomedicines12020448
Abbott SM, Malkani RG, Zee PC. Circadian disruption and human health: a bidirectional relationship. Eur J Neurosci. 2020;51(1):567-83. DOI: https://doi.org/10.1111/ejn.14298
Beebe DW. Cognitive, behavioral, and functional consequences of inadequate sleep in children and adolescents. Pediatr Clin North Am. 2011;58(3):649-65. DOI: https://doi.org/10.1016/j.pcl.2011.03.002
Siegel JM. The neurotransmitters of sleep. J Clin Psychiatry. 2004;65:4-7.
Ren Q, Gu M, Fan X. Circadian clock genes and insomnia: molecular mechanisms and therapeutic implications. Ann Med. 2025;57(1):2576643. DOI: https://doi.org/10.1080/07853890.2025.2576643
Finan PH, Smith MT. The comorbidity of insomnia, chronic pain, and depression: dopamine as a putative mechanism. Sleep Med Rev. 2013;17(3):173-83. DOI: https://doi.org/10.1016/j.smrv.2012.03.003
Feuth T. Interactions between sleep, inflammation, immunity and infections: a narrative review. Immun Inflamm Dis. 2024;12(10):e70046. DOI: https://doi.org/10.1002/iid3.70046
Walker J, Muench A, Perlis ML, Vargas I. Cognitive behavioral therapy for insomnia (CBT-I): a primer. Klin Spec Psihol. 2022;11(2):123-37. DOI: https://doi.org/10.17759/cpse.2022110208
Baranwal N, Yu PK, Siegel NS. Sleep physiology, pathophysiology, and sleep hygiene. Prog Cardiovasc Dis. 2023;77:59-69. DOI: https://doi.org/10.1016/j.pcad.2023.02.005
Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA(A) receptor modulators? Adv Pharmacol Sci. 2012;2012:416864. DOI: https://doi.org/10.1155/2012/416864
Richter G, Liao VWY, Ahring PK, Chebib M. The Z-drugs zolpidem, zaleplon, and eszopiclone have varying actions on human GABA(A) receptors containing γ1, γ2, and γ3 subunits. Front Neurosci. 2020;14:599812. DOI: https://doi.org/10.3389/fnins.2020.599812
Spadoni G, Bedini A, Rivara S, Mor M. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther. 2011;17(6):733-41. DOI: https://doi.org/10.1111/j.1755-5949.2010.00197.x
Wiegand MH. Antidepressants for the treatment of insomnia: a suitable approach? Drugs. 2008;68(17):2411-7. DOI: https://doi.org/10.2165/0003495-200868170-00001
Ariza-Salamanca DF, Venegas M, Parejo K, Amado S, Echeverry J, Calderón-Ospina CA. Expert consensus on the use of diphenhydramine for short-term insomnia: efficacy, safety, and clinical applications. J Clin Med. 2025;14(10):3297. DOI: https://doi.org/10.3390/jcm14103297
Khaledi-Paveh B, Maazinezhad S, Rezaie L, Khazaie H. Treatment of chronic insomnia with atypical antipsychotics: results from a follow-up study. Sleep Sci. 2021;14(1):27-32.
Tabish SA. Complementary and alternative healthcare: is it evidence-based? Int J Health Sci (Qassim). 2008;2(1):V-IX.
Sun SY, Chen GH. Treatment of circadian rhythm sleep-wake disorders. Curr Neuropharmacol. 2022;20(6):1022-34. DOI: https://doi.org/10.2174/1570159X19666210907122933
Grandner MA, Perlis ML. Treating insomnia disorder in the context of medical and psychiatric comorbidities. JAMA Intern Med. 2015;175(9):1472-3. DOI: https://doi.org/10.1001/jamainternmed.2015.3015
Lin C, Cheng C, Xia Y, Wang R, Zhang L, Han L, et al. Internet-delivered cognitive behavioral therapy for insomnia: the future of insomnia treatment with large language models. Sleep Med X. 2025;10:100157. DOI: https://doi.org/10.1016/j.sleepx.2025.100157
Rosenberg R, Citrome L, Drake CL. Advances in the treatment of chronic insomnia: a narrative review of new nonpharmacologic and pharmacologic therapies. Neuropsychiatr Dis Treat. 2021;17:2549-66. DOI: https://doi.org/10.2147/NDT.S297504
Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry. 2006;18(1):49-56. DOI: https://doi.org/10.1080/10401230500464711
Ebrahim IO, Howard RS, Kopelman MD, Sharief MK, Williams AJ. The hypocretin/orexin system. J R Soc Med. 2002;95(5):227-30. DOI: https://doi.org/10.1177/014107680209500503
Seol J, Fujii Y, Park I, Suzuki Y, Kawana F, Yajima K, et al. Distinct effects of orexin receptor antagonist and GABAA agonist on sleep and physical/cognitive functions after forced awakening. Proc Natl Acad Sci U S A. 2019;116(48):24353-8. DOI: https://doi.org/10.1073/pnas.1907354116
Zhou M, Liu R, Tang J, Tang S. Effects of new hypnotic drugs on cognition: a systematic review and network meta-analysis. Sleep Med X. 2023;6:100094. DOI: https://doi.org/10.1016/j.sleepx.2023.100094
Bollu PC, Kaur H. Sleep medicine: insomnia and sleep. Mo Med. 2019;116(1):68-75.
De la Herrán-Arita AK, Guerra-Crespo M, Drucker-Colín R. Narcolepsy and orexins: an example of progress in sleep research. Front Neurol. 2011;2:26. DOI: https://doi.org/10.3389/fneur.2011.00026
Schroeck JL, Ford J, Conway EL, Kurtzhalts KE, Gee ME, Vollmer KA, et al. Review of safety and efficacy of sleep medicines in older adults. Clin Ther. 2016;38(11):2340-72. DOI: https://doi.org/10.1016/j.clinthera.2016.09.010
Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;51:243-66. DOI: https://doi.org/10.1146/annurev-pharmtox-010510-100528
Ferrari LL, Park D, Zhu L, Palmer MR, Broadhurst RY, Arrigoni E. Regulation of lateral hypothalamic orexin activity by local GABAergic neurons. J Neurosci. 2018;38(6):1588-99. DOI: https://doi.org/10.1523/JNEUROSCI.1925-17.2017
Wang C, Wang Q, Ji B, Pan Y, Xu C, Cheng B, et al. The orexin/receptor system: molecular mechanism and therapeutic potential for neurological diseases. Front Mol Neurosci. 2018;11:220. DOI: https://doi.org/10.3389/fnmol.2018.00220
Yamanaka A, Tabuchi S, Tsunematsu T, Fukazawa Y, Tominaga M. Orexin directly excites orexin neurons through orexin 2 receptor. J Neurosci. 2010;30(38):12642-52. DOI: https://doi.org/10.1523/JNEUROSCI.2120-10.2010
Beig MI, Dampney BW, Carrive P. Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat. Neuropharmacology. 2015;89:146-56. DOI: https://doi.org/10.1016/j.neuropharm.2014.09.012
Kukkonen JP, Leonard CS. Orexin/hypocretin receptor signalling cascades. Br J Pharmacol. 2014;171(2):314-31. DOI: https://doi.org/10.1111/bph.12324
Żełabowski K, Petrov W, Wojtysiak K, Ratka Z, Biedka K, Wesołowski M, et al. Targeting the orexin system in the pharmacological management of insomnia and other diseases: suvorexant, lemborexant, daridorexant, and novel experimental agents. Int J Mol Sci. 2025;26(17):8700. DOI: https://doi.org/10.3390/ijms26178700
Onge ES, Phillips B, Rowe C. Daridorexant: a new dual orexin receptor antagonist for insomnia. J Pharm Technol. 2022;38(5):297-303. DOI: https://doi.org/10.1177/87551225221112546
Revell VL, Della Monica C, Mendis J, Hassanin H, Halter RJ, Chaplan SR, et al. Effects of the selective orexin-2 receptor antagonist JNJ-48816274 on sleep initiated in the circadian wake maintenance zone: a randomized trial. Neuropsychopharmacology. 2022;47(3):719-27. DOI: https://doi.org/10.1038/s41386-021-01175-3
Bonaventure P, Yun S, Johnson PL, Shekhar A, Fitz SD, Shireman BT, et al. A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects. J Pharmacol Exp Ther. 2015;352(3):590-601. DOI: https://doi.org/10.1124/jpet.114.220392
Xu TR, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: multifunctional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cell Signal. 2013;25(12):2413-23. DOI: https://doi.org/10.1016/j.cellsig.2013.07.025
Slosky LM, Caron MG, Barak LS. Biased allosteric modulators: new frontiers in GPCR drug discovery. Trends Pharmacol Sci. 2021;42(4):283-99. DOI: https://doi.org/10.1016/j.tips.2020.12.005
Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opin Drug Metab Toxicol. 2020;16(11):1063-78. DOI: https://doi.org/10.1080/17425255.2020.1817380
Young J, Lee E, Lindblad AJ, Falk J. Orexin antagonists for insomnia. Can Fam Physician. 2024;70(3):183-4. DOI: https://doi.org/10.46747/cfp.7003183
Xue T, Wu X, Chen S, Yang Y, Yan Z, Song Z, et al. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: a systematic review and network meta-analysis. Sleep Med Rev. 2022;61:101573. DOI: https://doi.org/10.1016/j.smrv.2021.101573
Cicala G, Barbieri MA, Russo G, Salvo F, Spina E. Safety of dual orexin receptor antagonist daridorexant: a disproportionality analysis of publicly available FAERS data. Pharmaceuticals. 2024;17(3):342. DOI: https://doi.org/10.3390/ph17030342
Etori K, Saito YC, Tsujino N, Sakurai T. Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1m, on sleep/wakefulness states in mice. Front Neurosci. 2014;8:8. DOI: https://doi.org/10.3389/fnins.2014.00008
Furukawa Y, Sakata M, Furukawa TA, Efthimiou O, Perlis M. Initial treatment choices for long-term remission of chronic insomnia disorder in adults: a systematic review and network meta-analysis. Psychiatry Clin Neurosci. 2024;78(11):646-53. DOI: https://doi.org/10.1111/pcn.13730
Morin CM. Combined therapeutics for insomnia: should our first approach be behavioral or pharmacological? Sleep Med. 2006;7:S15-9. DOI: https://doi.org/10.1016/j.sleep.2006.03.005
Downloads
Published
How to Cite
Issue
Section
